MGI Partners with National Cancer Centre Singapore to Undergo Comprehensive Genomic Profiling of Asian-Prevalent Cancers

MGI Tech Singapore Pte, Ltd. (“MGI”), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore (“NCCS”) to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI’s core DNBSEQ™ technology.

A conversation with researcher Kevin Esvelt on the urgency of improving biosecurity measures

If you ask a chatbot how to cause a pandemic, it will suggest the 1918 influenza virus, according to researcher Kevin Esvelt. It will even

May 22, 2024

Mental health screening tools for kids are 30 years out of date

Suicide is the second leading cause of death among children aged 10 to 14 in the U.S. That’s evidence of a systemic failure in identifying

April 10, 2024

FDA Approves Novel Treatment for UTIs

The FDA approved oral sulopenem etzadroxil and probenecid (Orlynvah) to treat uncomplicated urinary tract infections (uUTIs) caused by certain bacteria in women with limited or

October 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.